舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁

Clinical observation of Shugan Jieyu Capsule combined with citalopram on PSD

目的探讨舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁(PSD)的效果,以及对神经功能缺损症状、日常生活能力的影响。方法将64例脑卒中后抑郁患者随机均分为舒肝解郁胶囊联合西酞普兰组(观察组)和西酞普兰组(对照组),在治疗前和治疗后1、2、4、6周分别用汉密尔顿抑郁量表(HAMD)评分评定其疗效,美国国立卫生研究院卒中量表(NIHSS)和日常生活活动能力Barthel指数评分并加以比较。结果观察组和对照组总有效率分别为70.1%和61.3%,观察组疗效优于对照组(P<0.05)。对照组与观察组均未见明显不良反应,差异无统计学意义(P>0.05)。结论舒肝解郁胶囊联合西酞普兰对改善脑卒中后抑郁及神经功能缺损症状和日常生活能力效果较明显,优于单一药物治疗。

Object To study the clinical effect of Shugan Jieyu Capsule combined with citalopram on PSD and its impact on daily life ability and the defect symptom of neural function. Methods 64 cases of PSD were randomly divided into the observation group （Shugan Jieyu Capsule combined with citalopram） and the control group （citalopram only）. Hamilton rating scale for depression（HAMD）, national institutes of health stroke scale（NIHSS）, Barthel index score and Treatment Emergent Symptoms Scale （TESS） were used and compared in the two groups for week l, 2,4,6. Results The total efficacy were 70. 1% （observation group） and 61.3 % （ control group）. The difference was significant （ P 〈 0.05）. There was no obvious ad- verse reaction in control group and observation group, and the difference was not significant （ P 〉 0.05 ）. Conclusion Shugan Jieyu Capsule combined with citalopram has obvious effect on PSD. The combination therapy, the ideal drug for PSD, is better than single drug treatment.